What makes Yupelri different from other COPD inhalers?
Yupelri is a once-daily inhaled medicine for chronic obstructive pulmonary disease (COPD). It contains revefenacin, which is a long-acting muscarinic antagonist (LAMA). As a LAMA, it works by relaxing airway muscles and reducing bronchoconstriction, which helps improve breathing and prevent worsening of COPD symptoms. [1]
Compared with many COPD inhalers that are taken using metered-dose inhalers or dry powder devices, Yupelri is a nebulized solution, meant for use in a nebulizer. [1]
Yupelri vs Spiriva: are they the same type of drug?
Both Yupelri (revefenacin) and Spiriva are LAMA medications used for COPD, but they are not identical products and may be used differently depending on the formulation/device. Yupelri is the revefenacin LAMA delivered as a nebulized solution and given once daily. [1]
Yupelri vs LABA and LABA/LAMA combinations
Yupelri is a LAMA. Other common COPD controller drugs are:
- LABAs (long-acting beta agonists), which act on different receptors to relax airways.
- Combination inhalers that include both a LAMA and a LABA, which target two mechanisms.
So Yupelri differs by having only the LAMA mechanism (and by being nebulized), rather than being a LABA or a LAMA/LABA combination product. [1]
Why “once-daily nebulizer” can matter for patients
Some people find nebulizers easier than using inhaler devices correctly, especially if coordination is difficult. Yupelri is designed for once-daily use via nebulization, which can be a practical difference from inhaler-based COPD medications. [1]
What side effects are patients most likely to ask about?
Like other LAMA-type inhaled treatments, Yupelri can cause inhalation-related side effects such as dry mouth. Other effects reported with COPD inhaled therapies can vary by patient and by combination with other medicines. [1]
Can you use Yupelri with other COPD medicines?
Yupelri is typically used as a maintenance (controller) treatment for COPD and can be prescribed alongside other COPD therapies depending on the patient’s severity and symptom control. Your clinician decides what to pair it with and what to stop to avoid duplicating therapies. [1]
---
Sources
1. https://www.yupelri.com/